Close

Portola Pharma (PTLA) Says IndexXa MAA Accepted for Review in Europe

Go back to Portola Pharma (PTLA) Says IndexXa MAA Accepted for Review in Europe

Portola Pharma (PTLA) Receives CRL from FDA for Andexanet Alfa

August 18, 2016 6:16 AM EDT

Portola Pharmaceuticals Inc. (Nasdaq: PTLA) announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for AndexXa (andexanet alfa). An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to... More

Portola Pharma (PTLA) Drops 21% With Andexanet PDUFA Looming

August 17, 2016 3:29 PM EDT

Portola Pharma (NASDAQ: PTLA) declined over 20% and was halted on a limit-down pause Wednesday. The company's andexanet alfa PDUFA is today, August 17, 2016. The PDUFA date is the goal date for the FDA to complete its review of the BLA.

... More

Portola Pharma (PTLA) Halted on LUDP

August 17, 2016 3:14 PM EDT

Portola Pharma (NASDAQ: PTLA) Halted on LUDP

... More